Expression of CLDN6 in tissues of gastric cancer patients: Association with clinical pathology and prognosis

Gao,Fangmei; Li,Mingdong; Xiang,Rui; Zhou,Xin; Zhu,Lianying; Zhai,Yi

doi:10.3892/ol.2019.10129

Expression of CLDN6 in tissues of gastric cancer patients: Association with clinical pathology and prognosis

Authors:
- Fangmei Gao
- Mingdong Li
- Rui Xiang
- Xin Zhou
- Lianying Zhu
- Yi Zhai
View Affiliations

Affiliations: Department of Gastroenterology (I), Central Hospital of Zibo, Zibo, Shandong 255036, P.R. China, Department of Gastroenterology (II), Central Hospital of Zibo, Zibo, Shandong 255036, P.R. China, Department of Oncology (I), Central Hospital of Zibo, Zibo, Shandong 255036, P.R. China
Published online on: March 8, 2019 https://doi.org/10.3892/ol.2019.10129
Pages: 4621-4625

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Expression of claudin‑6 (CLDN6) in the tissues of gastric cancer patients and its association with clinical pathology and prognosis were investigated. A retrospective analysis was performed on 213 gastric cancer patients diagnosed and surgically treated in the Central Hospital of Zibo from January 2010 to January 2013. Cancer and normal adjacent tissues were obtained from the patients to detect the expression level of CLDN6 using reverse transcription‑quantitative PCR (RT‑qPCR). The association between the expression level of CLDN6 and the clinical and pathological features, as well as the prognosis of gastric cancer patients was analyzed. The expression level of CLDN6 was significantly lower in gastric cancer tissues than that in adjacent tissues (t=23.350, P<0.001). The expression level of CLDN6 was associated with age, lymph node metastasis, pathological staging, and distant metastasis (P<0.05). In this study, patients were separated into CLDN6 high‑expression group (≥1.42) with 107 patients and CLDN6 low‑expression group (<1.42) with 106 patients, with the median expression level of CLDN6 as the boundary. The 1‑, 2‑ and 3‑year survival rates of patients in the CLDN6 low‑expression group were 80.19, 60.38 and 48.11%, respectively, and those in the CLDN6 high‑expression group were 87.85, 73.83 and 66.36%, respectively. The survival rate was significantly better in the CLDN6 high‑expression group than that in the CLDN6 low‑expression group (P=0.009). In conclusion, the expression level of CLDN6 is low in the cancer tissues of gastric cancer patients, and associated with age, lymph node metastasis, pathological staging and distant metastasis. CLDN6 low expression has a certain negative impact on the prognosis of patients, and therefore, shows potential as an important indicator for the prognosis of gastric cancer patients.

View Figures

View References

1	Van Cutsem E, Sagaert X, Topal B, Haustermans K and Prenen H: Gastric cancer. Lancet. 388:2654–2664. 2016. View Article : Google Scholar : PubMed/NCBI
2	Correa P: Diet and gastric cancer. Diet, Nutrition and Cancer: A Critical Evaluation. Reddy BS and Cohen AL: 1. 1st. CRC Press; pp. 1–10. 2017
3	Oki E, Tokunaga S, Emi Y, Kusumoto T, Yamamoto M, Fukuzawa K, Takahashi I, Ishigami S, Tsuji A, Higashi H, et al Kyushu Study Group of Clinical Cancer, : Surgical treatment of liver metastasis of gastric cancer: A retrospective multicenter cohort study (KSCC1302). Gastric Cancer. 19:968–976. 2016. View Article : Google Scholar : PubMed/NCBI
4	Lee YC, Chiang TH, Chou CK, Tu YK, Liao WC, Wu MS and Graham DY: Association between Helicobacter pylori eradication and gastric cancer incidence: A systematic review and meta-analysis. Gastroenterology. 150:1113–1124.e5. 2016. View Article : Google Scholar : PubMed/NCBI
5	Karimi P, Islami F, Anandasabapathy S, Freedman ND and Kamangar F: Gastric cancer: Descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 23:700–713. 2014. View Article : Google Scholar : PubMed/NCBI
6	Kim JW, Nam KH, Ahn SH, Park DJ, Kim HH, Kim SH, Chang H, Lee JO, Kim YJ, Lee HS, et al: Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. Gastric Cancer. 19:42–52. 2016. View Article : Google Scholar : PubMed/NCBI
7	Yamada T, Yoshikawa T, Taguri M, Hayashi T, Aoyama T, Sue-Ling HM, Bonam K, Hayden JD and Grabsch HI: The survival difference between gastric cancer patients from the UK and Japan remains after weighted propensity score analysis considering all background factors. Gastric Cancer. 19:479–489. 2016. View Article : Google Scholar : PubMed/NCBI
8	Shimada H, Noie T, Ohashi M, Oba K and Takahashi Y: Clinical significance of serum tumor markers for gastric cancer: A systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer. 17:26–33. 2014. View Article : Google Scholar : PubMed/NCBI
9	Sahin U, Tureci O, Koslowski M, Walter K, Woll S, Kreuzberg M, Hubner B and Erdeljan M: Antibodies specific for claudin 6 (CLDN6). US Patent 9,487,584. Filed November 11, 2010; issued August 11, 2016.
10	Nelhűbel GA, Károly B, Szabó B, Lotz G, Kiss A, Tóvári J and Kenessey I: The prognostic role of claudins in head and neck squamous cell carcinomas Pathol. Oncol Res. 20:99–106. 2014. View Article : Google Scholar
11	Zhang WN, Li W, Wang XL, Hu Z, Zhu D, Ding WC, Liu D, Li KZ, Ma D and Wang H: CLDN1 expression in cervical cancer cells is related to tumor invasion and metastasis. Oncotarget. 7:87449–87461. 2016. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, Negri E, La Vecchia C and Lunet N: Worldwide trends in gastric cancer mortality (1980–2011), with predictions to 2015, and incidence by subtype. Eur J Cancer. 50:1330–1344. 2014. View Article : Google Scholar : PubMed/NCBI
14	Rugge M, Fassan M and Graham DY: Epidemiology of gastric cancer. Gastric Cancer. Strong VE: (1st). Springer International Publishing. (Switzerland). 23–34. 2015. View Article : Google Scholar : PubMed/NCBI
15	Sano T: Gastric cancer: Asia and the world. Gastric Cancer. 20 Suppl 1:1–2. 2017. View Article : Google Scholar : PubMed/NCBI
16	Graham DY: Helicobacter pylori update: Gastric cancer, reliable therapy, and possible benefits. Gastroenterology. 148:719–31.e3. 2015. View Article : Google Scholar : PubMed/NCBI
17	Merchant SJ, Kim J, Choi AH, Sun V, Chao J and Nelson R: A rising trend in the incidence of advanced gastric cancer in young Hispanic men. Gastric Cancer. 20:226–234. 2017. View Article : Google Scholar : PubMed/NCBI
18	Arabzadeh A, Troy TC and Turksen K: Role of the Cldn6 cytoplasmic tail domain in membrane targeting and epidermal differentiation in vivo. Mol Cell Biol. 26:5876–5887. 2006. View Article : Google Scholar : PubMed/NCBI
19	Yang M, Li Y, Shen X, Ruan Y, Lu Y, Jin X, Song P, Guo Y, Zhang X, Qu H, et al: CLDN6 promotes chemoresistance through GSTP1 in human breast cancer. J Exp Clin Cancer Res. 36:1572017. View Article : Google Scholar : PubMed/NCBI
20	Guo Y, Lin D, Zhang M, Zhang X, Li Y, Yang R, Lu Y, Jin X, Yang M, Wang M, et al: CLDN6-induced apoptosis via regulating ASK1-p38/JNK signaling in breast cancer MCF-7 cells. Int J Oncol. 48:2435–2444. 2016. View Article : Google Scholar : PubMed/NCBI
21	Maruyama K: The most important prognostic factors for gastric cancer patients: A study using univariate and multivariate analyses. Scand J Gastroenterol. 22 Suppl 133:63–68. 1987. View Article : Google Scholar
22	Torres-Martínez AC, Gallardo-Vera JF, Lara-Holguin AN, Montaño LF and Rendón-Huerta EP: Claudin-6 enhances cell invasiveness through claudin-1 in AGS human adenocarcinoma gastric cancer cells. Exp Cell Res. 350:226–235. 2017. View Article : Google Scholar : PubMed/NCBI